CAR-T Therapy in China
More Options. More Hope. A Clearer Path Forward.
RegenComp helps international patients access world-class CAR-T cell therapy in China through expert navigation, trusted hospital partnerships and end-to-end support.
A Brighter Tomorrow
Independent Healthcare Navigation
Your goals. Our expertise. A more connected journey.
blood cancers
eligibility review
treatment
monitoring
Which Cancers Can CAR-T Therapy Treat?
CAR-T therapy is mainly used for certain blood cancers. It is not suitable for every cancer.
Established hematologic indications
Lymphoma
(e.g. DLBCL, FL, MCL)
Leukemia
(e.g. B-ALL)
Multiple myeloma
(in selected cases)
Emerging / research applications
Other blood cancers and certain solid tumors are being studied in clinical trials.
Ongoing research
Expanding possibilities for more patients
Who May Be Eligible?
Eligibility depends on multiple medical factors and requires specialist evaluation.
So is our support.
Cancer type / target antigen
Specific subtypes
Prior treatment
Previous therapies and response
Relapsed / refractory status
Cancer that has returned or not responded
Organ function
Heart, liver, kidney and overall health
Diagnostic profile
Pathology, molecular testing, biomarkers
Product / trial availability
Approved products or clinical trials
How Does CAR-T Therapy Work?
A carefully coordinated, multi-stage process carried out by experienced medical teams.
Review medical records and overall health
Apheresis procedure to collect T cells
Genetic modification and expansion
Chemotherapy to prepare the body
Infusion of engineered T cells
In hospital monitoring for side effects
Ongoing assessment of response and health
Potential Benefits and Important Risks
Potential Benefits
-
Potential for durable response
-
Option for patients with limited treatment choices
-
Harnesses the patient's own immune system
-
Ongoing research may expand its use
Important Risks
-
Cytokine release syndrome (CRS)
Can cause fever, low blood pressure and other symptoms
-
Immune effector cell-associated neurotoxicity syndrome (ICANS)
Can affect thinking, speech and behavior
-
Infection risk
Due to low white blood cell counts
-
Cytopenias
Low blood cell counts that may require treatment
Why Consider CAR-T Therapy in China?
China has rapidly developed its cellular therapy capabilities, offering international patients expanded access to innovative treatments.
-
Specialized cancer centers
Leading hospitals with CAR-T experience
-
Advanced cellular therapy ecosystem
Growing expertise and infrastructure
-
Multidisciplinary evaluation
Comprehensive, team-based care
-
Clinical research access
Opportunities for innovative therapies
How RegenComp Supports International Patients
We provide navigation and coordination, working with trusted hospitals to help you access the right care.
Patient & Family
Your goals and needs
Navigation
Coordination · Communication · Support
Clinical Team
Trusted hospitals in China
Medical records organization
Help prepare and translate key documents
Medical interpretation
On-site or remote language support
Specialist communication
Coordinate with hospitals and clinical teams
Post-care handover
Share records and care plans for your local doctor
Appointment coordination
Arrange consultations, tests and treatment schedules
We are your navigation partner, not the treating hospital.
A Practical Decision Guide
Not sure what's next? This simple guide can help.
Proceed to Specialist Review
You may be ready for an expert evaluation.
Gather More Records
Additional information may help clarify your options.
Explore Other Options
CAR-T may not be suitable, but other treatments may be available.
Frequently Asked Questions
Find quick answers to common questions about CAR-T therapy in China.
What is the success rate of CAR-T therapy in China?
Response rates vary by cancer type and prior therapies. In clinical studies and major cancer centers in China, complete remission rates for relapsed/refractory B-ALL and certain lymphomas have ranged from 70% to 90%, comparable to international clinical outcomes.
How long does the treatment process take?
The standard process typically requires 4 to 8 weeks in China, including pre-treatment evaluations, cell collection (apheresis), 2–4 weeks of laboratory cell manufacturing, preconditioning chemotherapy, CAR-T infusion, and mandatory 2–3 weeks of inpatient monitoring.
What are the main side effects?
The primary risks are Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Specialized centers have established clinical protocols, including Tocilizumab and corticosteroids, to manage these effectively.
Can international patients receive CAR-T therapy in China?
Yes. Leading Chinese tertiary medical centers welcome overseas patients. RegenComp coordinates the entire medical record evaluation, invitation letters for medical visas, hospital admissions, and bilingual medical navigation.
How does RegenComp support me during the process?
RegenComp serves as your independent healthcare navigator—assisting with records organization, professional medical translation, liaison with top oncologists, scheduling appointments, on-site interpretation, and post-discharge coordination with your home physician.
Start With a Specialist Case Review
Share your medical information and receive expert guidance on next steps.
Professional, Independent, Patient-Focused.
RegenComp provides navigation and coordination services only. We do not provide medical treatment.